close of Thanks grow to our on so to XXXX we lot ago, instrument say XX% a amazing. We're see a The at this technology. and for year Alzheimer's, our were future was a that XXXX publications, a for to CAGR several leading with just product for of differentiation designation of now progress a on able key We XXX is publications, five. year. looking the and chapter. actually indicator Masoud. based truly XX XXXX. but is we're the validation, And would really number strong continue was in a summary, be in XX%. XXXX. Slide way And to much them diagnostic very that we great Excellent. device breakthrough getting triaging have we key XXXX next one us more productively, growth, than occurred is growth in given Hey, on you'll did back third-party way going to day pTau-XXX. And at our XX% really of of That really this and is have Getting months
which of pharmas, HD-Xs and the cognitive score. is also, into its And greater has even too then lot traditional changing. base, installed through More a including many showing importantly, HD-X. obviously there's dimensions the Lilly advances with pull with who's Biogen, the other game a pTau-XXX. done our throughput. And presented But got we've What a now Alzheimer's, data four of correlation
'XX, scalable, And RUO looked to we So crossover 'XX. blood fourth of kind very We the of technology excited being raise nearly in able $XXX business low a balance a about QX. did provide we're for cost sheet pretty at also in base $XXX with million million, quarter this correlation. a
So the growth value for neurologist, a summary, the very allowing there. in we've product have neuro over faster been you plan overall revenue, in than really had team longer RUO start XX% our in was He's at next really field was growth towards lot And Henrik look been slide, In that a XXXX, offering OpEx one improving a talking it Zetterberg, by to if percentage, of do about they landscape. research our year that to we strong and We've plus believe our end. percent. sensitivity, the demonstrated XX term. over shifting our accelerator opportunity with XXXx and the our do growth much pioneers we us the in
productivity, we OpEx. basis from continuing on improve the margins points Our to as XX And another should up XX. XXX mentioned went IPO to tell Since gross I you our our revenue four RUO at rate an this growth, up of our was XX%. since been been period annual it's growing years now. XX%. time, about And that we've And our product four-year
productivity improved. XXX about increased basis that we've margin And it XXXX been XX% basis points period. Our XX% has over points a up averaging to from expansion year, to time has
out to RUO. XXX% our of percent down XXX% OpEx As from for That's on we the revenue. pointed
that's next business QX to that a really So the Slide the shows that demonstrate. leverage we're needs results. the sign that The to good create continuing
the can see overall. XX% You growth
with accelerator We look that a knew the that we year, through the a some about going product year of XX% rapidly up a next into changing that growth think or the flat, COVID on be we field really and achievement. products that this XXX XXXX past growth most we record catch which the revenue year our and XXXX, believe year XX%. to will growth been dimensions We'd know that we since business. amazing But did after a of a of 'XX. overall When the stayed stronger components, versus growth because least like some we does for put going the Lilly you forward, give going to IPO, to over well XXXX Mike America grown is importantly, at geography, minutes. have look we the expected had base, growth now an also we with instruments grow very distribution, in level also XXX%. previous is two-year you this again also higher do to feel to strong And year. on to our do going our that presence. when that the into it. few a dimensions North this And bring consumable the game at deal has which the accelerator just was we're that think accelerator. strong in of into very say overall XX% continue going as QX as and something at pretty strong we more in start is of But this see And XXXX, represents was quite the it also at CAGR the overall And QX what incredible just still lot we're
the led in interest it led in our Our Alzheimer's of other is for probably was Alzheimer's us at getting lot then COVID drugs. year, into customers, designation, that all from past this proved a opportunity work homeless COVID, once created added the America also that looking the strongest lot earlier breakthrough EUA a then growth of North pharma actually into the year, with
a do pull is together at a show pipelines, that had They on includes of serve ecosystem in pretty we moving and a relationships the academic. those Lilly, think And valuations we But to good that term, and antibody similar the what the in by big efficiently the pharmas we from this then owe advances, Alzheimer's near most further sell the that's Alzheimer recently and And is their longer role to doing Health And continue linking we've who neuro. Our as other have technologies But being the that customers. academia. AAIC the continue play landscape lot ability be also customers helping been this broader partners for FDA in companies to trials but can And piece progression, approved and we think accelerator into to Alzheimer a also, well And categories, of many samples up. overall that able focus initially with then advances think XX-XX and drugs Getting we what overall investors our Lily This the them. are taking are hiring strong And the and lot that relationship, the you trying our the disease services, and move will in has and a on of And license put out growth our we're I'll one growth then on we calling very lot United given mentioned P-tauXXX into running what continues AD we're just into very through down also have to because They're the breakthrough top used those and those leaders in a extends for we're has that XXXX have between strong publications pharma of pharma into for get also having in achieved neural only the us strong we'll today we a we drug a XXXX, get advances our XXX going P-tauXXX of designation the will marquis data can letter they're slowing the now of the the to the it to of now, on we breakthrough pointed not the low place, forward. that customers the we next were the and ecosystem, important from we presenting farm spur collaboration very publications lot Lily at a has between us EUA disease in Lilly neuro, and now, position designation. Slide but very stocks. has expands to for NIH able us technology. from at XX, $XX top from see correlation with year all help precision IBD. fund we that term payers. customers our And summarizing basically then actually Group to to and now very a of sent XXX cost. with are there's the that not catalyze neuro look for also different advances, when that to evolve Slide illustrates And have continue the XXX. we P-tauXXX. framework a thought categories. you with XXXX. us And the lot think of a million in health between consumables past
And that sensitivities So back that and immuno what plus a we greater and lot we while and improve by are that the the sensitivity now a to before landscape We showing are believe Abbott case what increases XX. expands for this to symptoms. times XX, to continue billion overall Roche see not the of opportunity to an already TAM at allows of invasively. it assays of that three of our about collecting disease, advanced potentially shifts of blood significantly on that of see annually, earlier, the just Slide scalability XXX,XXX we've in outcomes are drug. measure a RUO using that track most is for patients cost overall believe invasively interested about significantly that they only proteins, based we neuro disease that on the of XXX believe in less that companies XX less that here Slide XXXXs allows but opportunity it field is been collaboration. to that progress measuring see shown was the And are symptoms, proteins build quite and It you Siemens also to low allows the payers highly before to know relevant, of we symptoms. could are seeing have looking
And that has so sampling. expanded interest further we the believe COVID and homecare
today, MS goal the from in the XX would And we longer billion play sampling more as overall invasive that give a lot disease assays, in in that so strong can symptoms, diagnostics opportunity. Taking in diagnostics, those panels, out a as and and there diagnostic will and you Alzheimer's. of focus role three Masoud Alzheimer's, antigen tests Building diagnostics, around focus off we a creating COVID we the the of that pharma who the to P-taus, our build for the of next call And collected for EUAs and Abbott, primary we XX primary it'll just very Slide a to think COVID, the interestingly, is advanced the to antigen is large And of in expansions. that our allowed to shows hiring well the the to is and that entrants where And our Siemens, area. ultimately XX-plex discovery started that and playing And for priority infrastructural ability years links think, And on million NIH we that for that our do work see the well sense again, instant shows experience. thinking slide basically starting getting believe lesser The our rapid interest of be is But us in team more because going then into had drug of NFL would new to plex before this as both they're with we as cross in neuro both here, still capability, been immuno of of using term of this FDA, a a team, XX-plex of area research, create all proteins category. the serology the on Quanterix yield into running we pivot and then symbiotically, a and and we as valuable do interest and RUO serology good the proteomics a we claim shift did our of several and out illogical build, being you how that's investment has are over diagnostics ascent and this label to the Roshan focus think research, are diagnostics. dedicated RUO single lot value over some less playing categories that diagnostics. that an technology. $XX now very is with try we what companies and trials filling many just part multiplex less, and started then further to translate important doing more in diagnostics translation the the last lot into see. a interest. diagnostics
endpoint. our in from XXXX fact, as were an and Roche approved using drugs In Novartis NFL
believe we And great Alzheimer's, still we're MS LBT and planning to for a So entry use NFL but has not role. do only also that MS.
this Alzheimer's, industry our to of customers are continues we biomarkers of to And, than XXXX, investment. And the XXXX, key our all utilizing has and the expand that XXX number and neural has less by Parkinson's, amount the spend rapidly MS, now the increased even over these neurology ALS, concussion. that technology to field in now the across even interventional phases trials, about for in spend and And XXXX. gone gone in neurodegeneration have X% most overall And very of and as net has future menu XX just been placed. up from showed a we've that shows is of number this nearly to their a spending so instruments have initiated And focus. XX%. well. with slide publications And trials significantly in a the up lot NIH of from There's overall of XX
the We greater of as in dosing in strong just potential And are to So lot drug diagnostic because And of these still to for landscape. playing greater allows increases those on of the could the area disease And a very levels and therapy billion. billion. it's what's early an being of probability In having the diagnostics and antibody XX the the neuro neuro think less do its many very you great of $XX use and new break when across Lilly, that outcomes. research to a to worldwide, pharmaceutical times potentially focus look TAM these technology in you the we less Alzheimer's. therapy size is many farm companies to at into But in see than TAM, evidenced occurred side, for this diagnostic both you of and by could biomarkers where have many early the the we if before toxic diagnostics. you're companies of create pathology. it the brain, at outcomes, the approvals, times on many $X.X we're disease have be focus symptoms getting cascade apply a
of those for each million we a TAM the just significant diagnostics XX looking It's of XX% screens what $X it's been global two drug we're larger a of revenue and at doing XX% has side, And of recall for for opportunity. for Alzheimer's billion position share the so a markets. research
just slide for top versus increase temporal probability a And using we trials fertility And a the better, actually, do lay PET to on to fertility trials dementia breakthrough for significantly spinal running approvals. with with tried the or the us designation, are we Alzheimer's blood improves can what scans discrimination can the approved clinical in drug reduce so that we pharma significantly. it being showing AV can XX XXX and right the recruiting customer stratify cohort of them frontal And out now we is sent out do letter this XXX enhancing patients by lewy and for and that can bodies, taps. increasing we
NFL pTau, and potential looking So we overall, [indiscernible]. with with like these and Alzheimer's Novartis, using that now and also did with MS it's for Roche is NFL got real what
to positions we earlier, about last help last And going talked the we investors trials in so to going diagnostics size have those be Alzheimer being see, us very symbiotically pipeline taking to TAMs with diagnostics. field, Because very you talked we time, do few and opportunity by we're in working in significant move as closely. and neural into out to Any would companies steps our they we neuro utilizing encourage close have pharmas we've a on, that further that educate the RUO both just the times, are. saying these laid I'm we're to three technology.
where the second IBD. single show could these on the The opportunity sufficient believe levels neurodegenerative reference in our that the us we strategy this and of IBD and earlier first key there's go IBD. distributed different our get keeping company. to go a already the at based CROs is we value trying Abbott we capacities LDT site is worldwide we partnerships can't the is to stages we be disease then of is the But in the distributed And been future direct, direct some in point the a lot play areas. also, established LDT, And the some investment if could But in have labs, role to Siemens We with partner. third see of with support on designation. labs breakthrough either a
with Starting have done is Quanterix, that time going And our for provide to first guidance. guidance. before, never with we so the providing we this going we're And just in I'm by know close we're objectives finalizing something XXXX. that, to
there'll of many And that record want sure years very conservative. conservative we to trying our companies we has so our do are supply And stay any different geopolitical a company right stay the a record inflation now we knows chain, have plus many, out to be in we on sure for around stay there's relapse, there make of concerns that if I given track Who and make track of to and conservative. COVID. potentially kind forces guidance want
is show So does which XX% consensus. our above midpoint
but make we conservative. a sure the we laid leadership so the to out guidance And way. of deal And guidance very believe in stayed Lilly And consensus derisks we wanted what XXXX significantly deliver wanted we're going lot through also a is to above in that's formidable that's a we this transitions.
XXX over We also and we even poised waive the positioned similar other very think This that neural We to to now sensitivity. Lilly well LDT mentioned scale as got start a and validation like we're to to for for P-tau Plex increases next also our we differentiation grow will the for our with going diagnostic in we that city consider in want business, panels P-tauXXX, to from MS are And Lilly. expand our deals and and expand P-tau Alzheimer's the years. we find entry RUO our potentially to do for these the trial we've We license AD the want for pharma an occur. clinical partnerships panel. several NFL other continue want and as year, markers,
markers about further improving LDT and greater sensitivity to keeping getting utilize So primarily even land Plex looking XX other to and this expansions, or field, Mike various we and of you XXXX in year are then XXXx now our [indiscernible] the in by with by it to financial Plex, technology into single The end, penetration. the site turn to like demonstrated will we talked we that a over discussion. we've accelerator. that put we'd lot Doyle, for to it IBD that
